Review: The Efficacy of Cannabidiol (CBD) as Potential Antipsychotic Medication
Keywords: Schizophrenia, treatment, cannabidiol, antipsychotics
AbstractPsychotic disorders such as schizophrenia are widespread and severely disabling; however, current pharmacological treatments are unsatisfactory due to major side effects. The current review discusses the therapeutic potential of cannabidiol (CBD), a non-psychoactive component of cannabis, as an antipsychotic drug. Research lines including studies based on animal models of psychosis, human experimental studies, neuroimaging studies, epidemiological studies, and clinical studies are reviewed. The studies described provide empirical support for the antipsychotic effects of CBD and indicate reduced side effects, high tolerability, and superior cost-effectiveness compared to regular antipsychotic medication. It is concluded that CBD may prove a safe and attractive alternative treatment for psychotic conditions. However, current evidence largely stems from experimental, non-clinical studies. Large-scale randomized clinical trials are needed before this can be implemented in practice.
Authors can use either their accepted author manuscript for:
- Use at a conference, meeting or for teaching purposes.
- Internal training.
- Sharing individual articles with colleagues for their research use (also known as 'scholarly sharing').
- Use in a subsequent compilation of the author's, or the supervisor's works.
- Inclusion in a thesis or dissertation.
- Reuse of portions or extracts from the article in other works.
- Preparation of derivative works (other than for commercial purposes).